Abstract
A wealth of both clinical and pre-clinical data has strongly implicated the eosinophil in the pathogenesis of asthma, highlighting this cell type as a potential target for novel anti-inflammatory approaches to asthma therapy. The Th2 lymphocyte derived cytokine Interleukin-5 (IL-5) has emerged as the key regulator of eosinophil production, thus identifying IL-5 as the principal molecular target for therapeutic intervention. This review highlights both the pharmaceutical approaches, and the major challenges, to the identification of small molecule and protein antagonists of the IL-5 receptor. Using examples of known inhibitors we discuss their current status and highlight the major development hurdles in progressing these molecules into the market place.
Keywords: receptor antagonists, granulocyte-macrophage, bronchial hyperreactivity, constrained peptides
Current Pharmaceutical Design
Title: Development of IL-5 Receptor Antagonists
Volume: 8 Issue: 20
Author(s): Iain Uings and Murray McKinnon
Affiliation:
Keywords: receptor antagonists, granulocyte-macrophage, bronchial hyperreactivity, constrained peptides
Abstract: A wealth of both clinical and pre-clinical data has strongly implicated the eosinophil in the pathogenesis of asthma, highlighting this cell type as a potential target for novel anti-inflammatory approaches to asthma therapy. The Th2 lymphocyte derived cytokine Interleukin-5 (IL-5) has emerged as the key regulator of eosinophil production, thus identifying IL-5 as the principal molecular target for therapeutic intervention. This review highlights both the pharmaceutical approaches, and the major challenges, to the identification of small molecule and protein antagonists of the IL-5 receptor. Using examples of known inhibitors we discuss their current status and highlight the major development hurdles in progressing these molecules into the market place.
Export Options
About this article
Cite this article as:
Uings Iain and McKinnon Murray, Development of IL-5 Receptor Antagonists, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393800
DOI https://dx.doi.org/10.2174/1381612023393800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Current Drug Targets Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Exhaled Nitric Oxide as a Potential Biomarker of Continuous Positive Airway Pressure Therapy for Severe Obstructive Sleep Apnea Patients
Current Respiratory Medicine Reviews Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets Application of Functional Genomics to Bronchial Asthma
Current Pharmacogenomics Surfactant Proteins in Smoking-Related Lung Disease
Current Topics in Medicinal Chemistry Recombinant Proteins and Peptides as Diagnostic and Therapeutic Reagents for Arthropod Allergies
Protein & Peptide Letters Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Advances and Patents about Grinding Equipments with Nano-Particle Jet Minimum Quantity Lubrication
Recent Patents on Nanotechnology Editorial (Thematic Issue: Immune Modulation)
Current Pharmaceutical Design Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Complications Following Stem Cell Therapy in Inflammatory Bowel Disease
Current Stem Cell Research & Therapy Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Medicinal Plant <i>Centipeda Minima</i>: A Resource of Bioactive Compounds
Mini-Reviews in Medicinal Chemistry